The novel class of GLP-1 receptor agonist and GIP combined medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, represent significant progress in the management . Despite https://cjc-1295471347.blogdon.net/semaglutide-a-detailed-look-59975492